Psychedelic Drugmaker Definium Surges on Depression Drug Success

Definium Therapeutics Inc. shares rally as much as 60% Monday after late-stage trial data showed “groundbreaking” results in the psychedelic drug developer’s experimental treatment for major depressive disorders.

Originally published on www.bloomberg.com — View original